Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04391803 · ClinicalTrials.gov registry record · NA
EvaLuate EndoVascular Treatment of Acutely Ruptured Shallow Intradural Aneurysms With the Pipeline™ Flex Embolization Device With Shield TEchnology™ (ELEVATE)
A NA study, sponsored by Medtronic Neurovascular Clinical Affairs.
- Terminated
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT04391803: Clinical Trial NA study, sponsored by Medtronic Neurovascular Clinical Affairs.
NCT04391803 is a NA study that was terminated before completion, run by Medtronic Neurovascular Clinical Affairs. The registered enrollment target is 25 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04391803, a NA study, was terminated before completion, sponsored by Medtronic Neurovascular Clinical Affairs.
- TERMINATED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the safety and effectiveness of the Pipeline™ Flex Embolization Device with Shield Technology™ in the treatment with acutely ruptured intracranial aneurysms.
Primary Outcome
Occlusion is measured by the Raymond Roy Scale. Significant stenosis is classified as ≤ 50%.
Interventions
- DEVICE Pipeline™ Flex Embolization Device with Shield Technology™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-05-06 |
| Est. Completion | 2025-10-20 |
| Phase | NA |
Why NCT04391803 stopped before completion
NCT04391803 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Pipeline™ Flex Embolization Device with Shield Technology™ is the first listed.
NCT04391803 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04391803 about?
NCT04391803 is a clinical study titled "EvaLuate EndoVascular Treatment of Acutely Ruptured Shallow Intradural Aneurysms With the Pipeline™ Flex Embolization Device With Shield TEchnology™ (ELEVATE)". The purpose of the study is to assess the safety and effectiveness of the Pipeline™ Flex Embolization Device with Shield Technology™ in the treatment with acutely ruptured intracranial aneurysms.
What is the current status of trial NCT04391803?
This trial is currently terminated. It is a NA study. The enrollment target is 25 participants. The study started on 2022-05-06. Estimated completion is 2025-10-20.
What interventions are being tested in trial NCT04391803?
The interventions under investigation include: Pipeline™ Flex Embolization Device with Shield Technology™ (DEVICE).
Who is sponsoring clinical trial NCT04391803?
This trial is sponsored by Medtronic Neurovascular Clinical Affairs, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04391803's enrollment target sits among peer trials
25 1712th of 2000 higher than 265 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI